- Report
- April 2026
- 140 Pages
Global
From €3635EUR$3,999USD£3,135GBP
- Report
- January 2026
- 185 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- November 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,527GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- June 2026
- 383 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- July 2025
- 150 Pages
Global
From €3408EUR$3,750USD£2,939GBP
- Report
- July 2025
- 85 Pages
Global
From €3500EUR$4,125USD£3,124GBP
- Report
- June 2025
- 100 Pages
United States
From €5408EUR$5,950USD£4,664GBP
- Report
- October 2025
- 90 Pages
Global
From €4408EUR$4,850USD£3,802GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- November 2024
- 265 Pages
Global
From €3795EUR$4,175USD£3,273GBP
- Report
- July 2023
- 152 Pages
Global
From €4226EUR$4,650USD£3,645GBP
- Report
- March 2024
- 202 Pages
Global
From €4499EUR$4,950USD£3,880GBP
- Report
- February 2024
- 64 Pages
Asia Pacific
From €2681EUR$2,950USD£2,312GBP
- Report
- January 2024
- 66 Pages
Europe
From €2681EUR$2,950USD£2,312GBP
- Report
- June 2025
- 320 Pages
Global
From €5408EUR$5,950USD£4,664GBP
- Report
- July 2024
- 154 Pages
Global
From €3863EUR$4,250USD£3,331GBP

Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma.
MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing.
Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more